Unattractive or morbid business ideas, such as cemetery management software, often face less competition. This lack of saturation means entrepreneurs willing to enter these "grim" niches have a higher probability of financial success and market capture.

ProKidney's CEO observes that over a 10-year period, the only significant change he saw in dialysis clinics was the addition of flat-screen TVs. This starkly illustrates the profound lack of clinical and technological innovation in a massive, life-sustaining industry, highlighting a huge opportunity for disruption.

First-time founders often fear competition. Experienced founders, however, see it as validation that a market exists. The absence of competitors is a major red flag that people may not want your product. It is easier to out-execute in a validated market than to create a new one.

While hype cycles focus on novel areas, significant value exists in established markets like hypertension. By targeting refractory patient populations with high unmet needs (e.g., the 20% of hypertension patients not properly treated), biotechs can create valuable assets with novel mechanisms in fields that appear saturated.

Augurex's CEO identified a major opportunity by noting that biomarker use in rheumatology was 10-15 years behind oncology. This "technology lag" between medical specialties signals a significant unmet need and a prime area for innovation, allowing proven concepts from one field to revolutionize another.

Investors often reject ideas in markets where previous companies failed, a bias they call "scar tissue." This creates an opportunity for founders who can identify a key change—like new AI technology or shifting consumer behavior—that makes a previously impossible idea now viable.

When evaluating revolutionary ideas, traditional Total Addressable Market (TAM) analysis is useless. VCs should instead bet on founders with a "world-bending vision" capable of inducing a new market, not just capturing an existing one. Have the humility to admit you can't predict market size and instead back the visionary founder.

Significant change doesn't come from the established core of an industry but from the margins. This is where smaller, private companies and overlooked founders operate, making private markets a crucial hunting ground for the most disruptive investment opportunities.

A key part of Eli Lilly's R&D strategy is tackling large-scale health problems that currently have no treatments and therefore represent a 'zero-dollar market.' This blue-ocean strategy contrasts with competitors who focus on areas with established payment pathways.